Adavosertib
- Generic Name
- Adavosertib
- Drug Type
- Small Molecule
- Chemical Formula
- C27H32N8O2
- CAS Number
- 955365-80-7
- Unique Ingredient Identifier
- K2T6HJX3I3
- Background
MK-1775 has been used in trials studying the treatment of LYMPHOMA, Neoplasms, Ovarian Cancer, Tongue Carcinoma, and Adult Glioblastoma, among others.
Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer
- Conditions
- Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2014-03-14
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 22
- Registration Number
- NCT02087241
- Locations
- 🇺🇸
Research Site, Nashville, Tennessee, United States
A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer
- Conditions
- Previously Treated Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2014-03-14
- Last Posted Date
- 2016-06-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 48
- Registration Number
- NCT02087176
- Locations
- 🇺🇸
Research Site, Milwaukee, Wisconsin, United States
Dose Escalation Trial of AZD1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas
- Conditions
- Adenocarcinoma of the Pancreas
- Interventions
- First Posted Date
- 2014-01-15
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 34
- Registration Number
- NCT02037230
- Locations
- 🇺🇸
University of Michigan Hospital, Ann Arbor, Michigan, United States
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
- Conditions
- Anaplastic AstrocytomaAnaplastic OligoastrocytomaDiffuse Intrinsic Pontine GliomaDiffuse Midline Glioma, H3 K27M-MutantGliosarcomaGlioblastoma
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Pharmacological StudyRadiation: Radiation Therapy
- First Posted Date
- 2013-08-14
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 46
- Registration Number
- NCT01922076
- Locations
- 🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States
🇺🇸Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States
Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma
- Conditions
- GlioblastomaRecurrent Glioblastoma
- Interventions
- First Posted Date
- 2013-05-08
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 74
- Registration Number
- NCT01849146
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations
- Conditions
- Advanced Malignant Solid Neoplasm
- Interventions
- First Posted Date
- 2013-04-09
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 208
- Registration Number
- NCT01827384
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States
A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2011-05-20
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 136
- Registration Number
- NCT01357161
A Study of Adavosertib (MK-1775) in Combination With Topotecan/Cisplatin in Participants With Cervical Cancer (MK-1775-008)
- Conditions
- Cervical Cancer
- Interventions
- First Posted Date
- 2010-02-26
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 7
- Registration Number
- NCT01076400
A Dose Escalation Study of Adavosertib(MK1775) in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2010-01-12
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 11
- Registration Number
- NCT01047007
A Dose Escalation Study of Adavosertib (MK-1775) in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001)
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 206
- Registration Number
- NCT00648648
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.